Analysts Are Bullish on Top Healthcare Stocks: Oric Pharmaceuticals (ORIC), Viking Therapeutics (VKTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) and Viking Therapeutics (VKTX – Research Report) with bullish sentiments.

Oric Pharmaceuticals (ORIC)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Oric Pharmaceuticals, with a price target of $16.00. The company’s shares closed last Wednesday at $6.00.

According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -40.1% and a 11.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Springworks Therapeutics, and Allogene Therapeutics.

Currently, the analyst consensus on Oric Pharmaceuticals is a Strong Buy with an average price target of $17.17, a 183.3% upside from current levels. In a report issued on October 24, J.P. Morgan also maintained a Buy rating on the stock with a $17.00 price target.

See today’s best-performing stocks on TipRanks >>

Viking Therapeutics (VKTX)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics today and set a price target of $33.00. The company’s shares closed last Wednesday at $10.67.

According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.8% and a 24.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Actinium Pharmaceuticals.

Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $34.67, a 225.2% upside from current levels. In a report issued on October 18, BTIG also maintained a Buy rating on the stock with a $36.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ORIC:

• Oric Pharmaceuticals price target raised to $17 from $14 at JPMorgan
• Oric Pharmaceuticals price target raised to $15 from $13 at Citi
• Oric announces initial data from ongoing ORIC-114 Phase 1 dose escalation
• Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
• ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023